115 related articles for article (PubMed ID: 14744729)
1. Expression of the high mobility group proteins HMGI(Y) correlates with malignant progression in Barrett's metaplasia.
Chen X; Lechago J; Ertan A; Ergun G; Verm R; Bridges M; Johnson C; Woods K; Meriano F; Chirala M; Younes M
Cancer Epidemiol Biomarkers Prev; 2004 Jan; 13(1):30-3. PubMed ID: 14744729
[TBL] [Abstract][Full Text] [Related]
2. Human erythrocyte glucose transporter (Glut1) is immunohistochemically detected as a late event during malignant progression in Barrett's metaplasia.
Younes M; Ertan A; Lechago LV; Somoano J; Lechago J
Cancer Epidemiol Biomarkers Prev; 1997 May; 6(5):303-5. PubMed ID: 9149888
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor-beta is expressed in Barrett's metaplasia and associated adenocarcinoma of the esophagus.
Akgun H; Lechago J; Younes M
Anticancer Res; 2002; 22(3):1459-61. PubMed ID: 12168823
[TBL] [Abstract][Full Text] [Related]
4. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
5. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
[TBL] [Abstract][Full Text] [Related]
6. Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia.
Yorke R; Younes A; Chirala M; Younes M
Eur J Cancer; 2003 Sep; 39(14):2099-102. PubMed ID: 12957466
[TBL] [Abstract][Full Text] [Related]
7. p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia.
Younes M; Ertan A; Lechago LV; Somoano JR; Lechago J
Dig Dis Sci; 1997 Apr; 42(4):697-701. PubMed ID: 9125634
[TBL] [Abstract][Full Text] [Related]
8. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Dorer R; Odze RD
Am J Surg Pathol; 2006 Jul; 30(7):871-7. PubMed ID: 16819330
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and risk stratification of Barrett's dysplasia by flow cytometric DNA analysis of paraffin-embedded tissue.
Choi WT; Tsai JH; Rabinovitch PS; Small T; Huang D; Mattis AN; Kakar S
Gut; 2018 Jul; 67(7):1229-1238. PubMed ID: 28642331
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
Morris CD; Armstrong GR; Bigley G; Green H; Attwood SE
Am J Gastroenterol; 2001 Apr; 96(4):990-6. PubMed ID: 11316217
[TBL] [Abstract][Full Text] [Related]
11. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
[TBL] [Abstract][Full Text] [Related]
12. p53 protein accumulation predicts malignant progression in Barrett's metaplasia: a prospective study of 275 patients.
Younes M; Brown K; Lauwers GY; Ergun G; Meriano F; Schmulen AC; Barroso A; Ertan A
Histopathology; 2017 Jul; 71(1):27-33. PubMed ID: 28226185
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus.
Younes M; Lechago J; Ertan A; Finnie D; Younes A
Hum Pathol; 2000 Apr; 31(4):434-8. PubMed ID: 10821489
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
Wani S; Rubenstein JH; Vieth M; Bergman J
Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
[TBL] [Abstract][Full Text] [Related]
15. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues.
Fang M; Lew E; Klein M; Sebo T; Su Y; Goyal R
Am J Gastroenterol; 2004 Oct; 99(10):1887-94. PubMed ID: 15447746
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
17. The significance of "indefinite for dysplasia" grading in Barrett metaplasia.
Younes M; Lauwers GY; Ertan A; Ergun G; Verm R; Bridges M; Woods K; Meriano F; Schmulen C; Johnson C; Barroso A; Schwartz J; McKechnie J; Lechago J
Arch Pathol Lab Med; 2011 Apr; 135(4):430-2. PubMed ID: 21466357
[TBL] [Abstract][Full Text] [Related]
18. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
[TBL] [Abstract][Full Text] [Related]
19. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD
Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
[TBL] [Abstract][Full Text] [Related]
20. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
